Dose–response of benazepril on biomarkers of the classical and alternative pathways of the renin–angiotensin–aldosterone system in dogs

[1]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[2]  K. Dorman,et al.  Retrospective evaluation of a dose‐dependent effect of angiotensin‐converting enzyme inhibitors on long‐term outcome in dogs with cardiac disease , 2021, Journal of Veterinary Internal Medicine.

[3]  É. Larouche-Lebel,et al.  Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease , 2020, Journal of veterinary internal medicine.

[4]  Arthur S Slutsky,et al.  Human recombinant soluble ACE2 in severe COVID-19 , 2020, The Lancet Respiratory Medicine.

[5]  G. Monteith,et al.  Echocardiographic parameters for the assessment of congestive heart failure in dogs with myxomatous mitral valve disease and moderate to severe mitral regurgitation. , 2020, Veterinary journal.

[6]  M. Stowasser,et al.  Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism. , 2020, Clinical chemistry.

[7]  M. Di Marcello,et al.  DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study. , 2020, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

[8]  M. Tetti,et al.  Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. , 2019, Hypertension.

[9]  R. Touyz,et al.  Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.

[10]  P. Solter,et al.  Plasma and tissue angiotensin‐converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease , 2019, Journal of veterinary internal medicine.

[11]  L. Halsey.  The reign of the p-value is over: what alternative analyses could we employ to fill the power vacuum? , 2019, Biology Letters.

[12]  J. Häggström,et al.  ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs , 2019, Journal of veterinary internal medicine.

[13]  M. Danhof,et al.  Sacubitril/valsartan (LCZ696) Significantly Reduces Aldosterone and Increases cGMP Circulating Levels in a Canine Model of RAAS Activation , 2018, bioRxiv.

[14]  M. Gyöngyösi,et al.  Low- and High-renin Heart Failure Phenotypes with Clinical Implications. , 2018, Clinical chemistry.

[15]  A. Hess,et al.  Aldosterone breakthrough in dogs with naturally occurring myxomatous mitral valve disease. , 2017, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

[16]  R. Santos,et al.  Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney , 2016, Scientific Reports.

[17]  C. Atkins,et al.  Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. , 2015, American journal of veterinary research.

[18]  M. Murias,et al.  Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors. , 2015, Current pharmaceutical design.

[19]  D. Curran‐Everett,et al.  The fickle P value generates irreproducible results , 2015, Nature Methods.

[20]  Y. Pinto,et al.  Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2014, European heart journal.

[21]  M. Danhof,et al.  Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs , 2014, Chronobiology international.

[22]  M. Danhof,et al.  Chronobiology of the renin-angiotensin-aldosterone system in dogs: relation to blood pressure and renal physiology , 2013, Chronobiology international.

[23]  Tiina Heliö,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2013, European heart journal.

[24]  B. Ploeger,et al.  Capturing the dynamics of systemic Renin-Angiotensin-Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs. , 2013, Journal of veterinary pharmacology and therapeutics.

[25]  M. Smolensky,et al.  Administration-Time Differences in Effects of Hypertension Medications on Ambulatory Blood Pressure Regulation , 2013, Chronobiology international.

[26]  M. Fink,et al.  Response to letter from Atkins et al. Capturing the dynamics of systemic Renin‐Angiotensin‐Aldosterone System (RAAS) peptides heightens the understanding of the effect of benazepril in dogs , 2012 .

[27]  A. Christopoulos,et al.  Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. , 2011, Clinical science.

[28]  G. Navis,et al.  Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. , 2011, Current vascular pharmacology.

[29]  C. Couto,et al.  White-coat effect on systemic blood pressure in retired racing Greyhounds. , 2011, Journal of veterinary internal medicine.

[30]  Xiaobai Li,et al.  Detection of congestive heart failure in dogs by Doppler echocardiography. , 2010, Journal of veterinary internal medicine.

[31]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.

[32]  R. Fukushima,et al.  The effect of angiotensin-converting enzyme inhibitors of left atrial pressure in dogs with mitral valve regurgitation. , 2010, Journal of veterinary internal medicine.

[33]  R. Horne,et al.  Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. , 2009, Journal of veterinary internal medicine.

[34]  T. Walther,et al.  Angiotensin-(1–7) and the G Protein-Coupled Receptor Mas Are Key Players in Renal Inflammation , 2009, PloS one.

[35]  F. Fyhrquist,et al.  Renin‐angiotensin system revisited , 2008, Journal of internal medicine.

[36]  J. Stern,et al.  Estimation of left ventricular filling pressure by use of Doppler echocardiography in healthy anesthetized dogs subjected to acute volume loading. , 2008, American journal of veterinary research.

[37]  R. Hamlin,et al.  Estimation of left ventricular filling pressure by Doppler echocardiography in dogs with pacing-induced heart failure. , 2008, Journal of veterinary internal medicine.

[38]  T. DeFrancesco,et al.  Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. , 2007, Journal of the American Veterinary Medical Association.

[39]  E. Schiffrin.  Effects of Aldosterone on the Vasculature , 2006, Hypertension.

[40]  A. Voors,et al.  Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. , 2006, International journal of cardiology.

[41]  P. Toutain,et al.  Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors. , 2004, Journal of veterinary pharmacology and therapeutics.

[42]  Cathy A. Brown,et al.  Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. , 2003, American journal of veterinary research.

[43]  S. A. Brown,et al.  Effect of renal insufficiency on the pharmacokinetics and pharmacodynamics of benazepril in cats. , 2002, Journal of veterinary pharmacology and therapeutics.

[44]  M. Uechi,et al.  Dose-dependent inhibition of angiotensin converting enzyme by enalapril in cats. , 2002, The Journal of veterinary medical science.

[45]  P. Toutain,et al.  Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. , 2000, The Journal of pharmacology and experimental therapeutics.

[46]  J. Pouchelon.  The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. , 1999, Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology.

[47]  A. D. Jernigan,et al.  Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. , 1998, Journal of the American Veterinary Medical Association.

[48]  R. Hamlin,et al.  Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles. , 1998, Journal of veterinary internal medicine.

[49]  M. Takahashi,et al.  Hemodynamic changes during administration of drugs for mitral regurgitation in dogs. , 1998, The Journal of veterinary medical science.

[50]  R. Hamlin,et al.  Effects of enalapril on exercise tolerance and longevity in dogs with heart failure produced by iatrogenic mitral regurgitation. , 1996, Journal of veterinary internal medicine.

[51]  G. Kaiser,et al.  Pharmacokinetics of the active metabolite of benazepril, benazeprilat, and inhibition of plasma angiotensin-converting enzyme activity after single and repeated administrations to dogs. , 1995, American journal of veterinary research.

[52]  J. Woodfield.  Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group. , 1995, Journal of veterinary internal medicine.

[53]  D. Sisson,et al.  Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group. , 1995, Journal of veterinary internal medicine.

[54]  R. Dilley,et al.  Mineralocorticoids, hypertension, and cardiac fibrosis. , 1994, The Journal of clinical investigation.

[55]  R. Carey,et al.  Effects of angiotensin converting enzyme inhibition, sodium depletion, calcium, isoproterenol, and angiotensin II on renin secretion by individual renocortical cells. , 1992, Endocrinology.

[56]  J. Hall.  Control of blood pressure by the renin‐angiotensin‐aldosterone system , 1991, Clinical cardiology.

[57]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[58]  J. Bright,et al.  Captopril provides sustained hemodynamic benefits in dogs with experimentally induced mitral regurgitation. , 1990, Veterinary surgery : VS.

[59]  F. Smith,et al.  The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. , 1976, The Journal of clinical investigation.

[60]  M. Danhof,et al.  Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? , 2015, Reviews of physiology, biochemistry and pharmacology.

[61]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[62]  E. Pesavento.  What Have We Learned ? , 2006 .

[63]  H. Pedersen,et al.  Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. , 2002, Journal of veterinary internal medicine.

[64]  G. Sanz,et al.  Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. , 2000, European heart journal.

[65]  K. Swedberg,et al.  Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. , 1999, European heart journal.